Patient agreement to systemic anti-cancer

therapy (SACT)	Patient's first name(s):
Cemiplimab	Date of birth:
	NHS number:(or other identifier)
Hospital/NHS Trust/NHS Board:	Special requirements: (eg other language/other communication method)
Responsible consultant: Name:	
Job title:	
Name of proposed course of treatment (include	de brief explanation if medical term not clear)
Cemiplimab for the treatment of squamous cell car	rcinoma of the skin.
☐ Cemiplimab is given intravenously every 21 days ((one cycle).
☐ Treatment is continued for up to 2 years, or less in toxicity or withdrawal of consent.	the event of disease progression, unacceptable
Where will I have treatment? ☐ Outpatient ☐ Day unit/case ☐ Inpatient [☐ Other:

Patient details

Patient's surname/family name:

Statement of health professional

(to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in the hospital/Trust/NHS board's consent policy)

\overline{V}	Tick	all	relevar	nt b	oxes

Пι	confirm the	nationt	hae	canacity	to.	avin	concan	ŧ
ı I I	-сопшти те	Danem	1145	CAUACIIV	1()	uive	consen	1

	l bovo	explained	l tha agus	oo of tre	atmont	and into		opofit t	, the	nationt
ıı	I nave	explained	I the colli	SE Of tre	atment	and inte	מחבח r	nenetit ta	n the	natient

The intended benefits (there are no guarantees about outcome)

Curative – to	give you	the best	possible chance	of being	cured

and reduce the risk of the cancer coming back

To be retained in patient notes Prepared by Pharmacist: Lucy Cox Checked by Pharmacist: Laura Ferro López Checked by Consultant: Heather Shaw

Date of issue: Feb-24; Version 1; Review date: Feb-27 Approved by: Janine Mansi UK SACT Board Check cruk.org/sact_consent for latest version Cemiplimab

Disease control or palliative – the aim is not to cure, but to control or shrink the disease and improve both quality of life and survival.

Adjuvant – therapy given after surgery or radiotherapy to reduce the risk of the cancer coming back.

Statement of health professional

Patient identifier/label

You may have one or more of the side effects listed						
 Other risks: Treatment uncommonly causes inflammation of: Brain or nerves: confusion, memory problems, seizures, numbness, tingling, weakness Eyes: dry, itchy, watery eyes, pain, vision changes Pancreas: tummy pain, feeling or being sick Heart muscle: chest pain, palpitations, irregular rhythm, changes in heart function Bladder: frequent or painful urination, blood in the urine Rarely, the immune system may attack groups of blood cells causing other blood conditions Side effects may need treatment with steroids or medicines to suppress the immune system. These medicines have side effects that are sometimes severe. You may need hormone 						
replacement. These side effects may be permanent and need long-term treatment. All intravenous drugs may leak out the vein and damage the tissue around (extravasation). Tell a nurse straight away if you have any stinging, pain, redness, swelling around the vein. It's uncommon but important to deal with quickly. Cancer and treatment for cancer can increase your risk of developing a blood clot (thrombosis) causing pain, redness, swelling in an arm or leg, breathlessness, chest pain, a stroke. Tell your						
doctor straight away if you have any symptoms. You may have blood tests to check for viruses (Hepatitis B, Hepatitis C, HIV, or more unusual infections). Infections like these could worsen or become active again if you've had them before, needing medicines to prevent or treat infection. Some anti-cancer medicines can damage ovaries and sperm. This may lead to infertility and/or early menopause.						
 Some anti-cancer medicines may damage the development of a baby in the womb. It is important not to become pregnant or make someone else pregnant during treatment and for 4 months after. Use effective contraception. Complications of treatment can very occasionally be life-threatening and may result in death. The risks are different for every individual. Potentially life- threatening complications include those listed on this form, but, other, exceedingly rare side-effects may also be life threatening. 						

To be retained in patient notes Prepared by Pharmacist: Lucy Cox Checked by Pharmacist: Laura Ferro López Checked by Consultant: Heather Shaw Date of issue: Feb-24; Version 1; Review date: Feb-27 Approved by: Janine Mansi UK SACT Board Check cruk.org/sact_consent for latest version **Cemiplimab**

Statement of health professional

Patient identific	er/label
-------------------	----------

Any other risks and information:	
☐ I have discussed the intended benefit and risks available alternative treatments (including no treat	_
☐ I have discussed the side effects of the recommendation of the future, and that there may be the rare or have not yet been reported. Each patient may be the future of	be some side effects not listed because they are
☐ I have discussed what the treatment is likely to timing of the treatment, blood and any additional to	• • • • • • • • • • • • • • • • • • • •
☐ I have explained to the patient, that they have should contact the responsible consultant or team	·
I have discussed concerns of particular importation (please write details here):	ance to the patient in regard to treatment
Clinical management guideline/Protocol co	ompliant (please tick): ase document reason here:
The following written information has been provided: Information leaflet for Cemiplimab	Health professional details: Signed:
24 hour alert card or SACT advice service contact details	Date:
☐ SACT treatment record (cruk.org/treatment-record)	Job title:
Other, please state:	
Statement of interpreter (where Interpreter booking reference (if applicable): I have interpreted the information above to the patie believe they can understand.	
Signed:	Date:
Name (PRINT):	Job title:

Statement of patient

Patient identifier/label

your own copy of the form which describes the be	has been planned in advance, you should already have enefits and risks of the proposed treatment. If not, you er questions, do ask – we are here to help you. You have ng after you have signed this form.		
☐ I have had enough time to consider my option	ns and make a decision about treatment.		
☐ I agree to the course of treatment described	on this form.		
A witness should sign below if the patient is unab parental responsibility will be asked to sign for yo	ole to sign but has indicated their consent. A person with bung people under the age of 16 years.		
Patient's signature:			
Name (PRINT):	Date:		
Person with parental responsibility/witness' signa	iture:		
Name (PRINT):	Date:		
Confirmation of consent (health professional to complete when the patient attends for treatment, if the patient has signed the form in advance) On behalf of the team treating the patient, I have confirmed that the patient has no further questions and wishes the course of	patients Contact details (if patient wishes to discuss options later):		
treatment/procedures to go ahead. Signed:	Contact your hospital team if you have any questions about cancer and its treatment.		
Date:	Cancer Research UK can also help answer your		
Name (PRINT):	questions about cancer and treatment. If you want to talk in confidence, call our information		
Job title:	nurses on freephone 0808 800 4040, Monday to Friday, 9am to 5pm. Alternatively visit cruk.org for		
Important notes: (tick if applicable)	more information.		
☐ See also advance decision to refuse treatment☐ Patient has withdrawn consent (ask patient to sign and date here)	These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT.		
Signed: Date:	The project is supported by Cancer Research UK. This does not mean you are		
	taking part in a clinical trial.		

To be retained in patient notes Prepared by Pharmacist: Lucy Cox Checked by Pharmacist: Laura Ferro López Checked by Consultant: Heather Shaw Date of issue: Feb-24; Version 1; Review date: Feb-27 Approved by: Janine Mansi UK SACT Board Check cruk.org/sact_consent for latest version Cemiplimab

taking part in a clinical trial.

Guidance for health professionals

(to be read in conjunction with the hospital's consent policy)

Patient identifier/label

What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2020 (gmc-uk.org/guidance). Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (doh.gov.uk).

Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. For young people, it is good practice to involve those with parental responsibility in the consent discussions, unless specifically asked not to. A person with parental responsibility must sign this form for a child or young person under the age of 16. Such patients should be given the opportunity to 'assent' to treatment if they wish. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

When NOT to use this form

If the patient lacks the capacity to give consent, you should use an alternative form available for this purpose (dependent on patient age). A patient lacks capacity if they have an impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- retain that information in their mind
- use or weigh this information as a part of their decision making process, or

 communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

Information

Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. If patients make clear they have particular concerns about certain kinds of risk, you should ensure that they are informed about these risks, even if very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

NHS Scotland

NHS Scotland staff should refer to Healthcare Improvement Scotland. Guidance on consent for SACT and local NHS Board guidance on consent aligned to the Scottish legal framework.

References

- 1. Summary of Product Characteristics for individual drugs: medicines.org.uk/emc
- Cancer Research UK: cruk.org/aboutcancer/treatment/drugs
- Macmillan Cancer Support: macmillan.org.uk/cancer-information-andsupport/treatments-and-drugs
- 4. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent form